Clinical Trials on 中度或重度 COVID-19 患者 in China
总计57个结果
-
Shanghai Vinnerna Biosciences Co., Ltd.Sponsor GmbH终止
-
Westlake Pharmaceuticals (Hangzhou) Co., Ltd.招聘中
-
The First Affiliated Hospital of Guangzhou Medical...完全的
-
Second Affiliated Hospital, School of Medicine,...主动,不招人
-
Shanghai JunTop Biosciences Co., LTDSponsor GmbH终止
-
Shanghai Vinnerna Biosciences Co., Ltd.Sponsor GmbH完全的
-
Jiangsu HengRui Medicine Co., Ltd.尚未招聘接受基于化疗方案的抗肿瘤治疗且具有中度至高度发热性中性粒细胞减少症 (FN) 风险的非髓系恶性肿瘤患者中国
-
Shanghai Hengrui Pharmaceutical Co., Ltd.邀请报名
-
The Second Hospital of Nanjing Medical University撤销COVID-19 Complicated With Refractory Intestinal Infections中国
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine未知
-
Zhong WangThe First Affiliated Hospital of Dalian Medical University; North China University of Science... 和其他合作者暂停
-
Jiangsu HengRui Medicine Co., Ltd.招聘中
-
Fujian Shengdi Pharmaceutical Co., Ltd.招聘中
-
Fujian Medical University招聘中
-
Kun Hua招聘中
-
Samsung Medical Center完全的弥漫性大 B 细胞淋巴瘤或滤泡性淋巴瘤患者 | 接受 Rituximab-CHOP 或 Rituximab-CVP 治疗的患者大韩民国, 马来西亚, 新加坡, 中国
-
Chinese Academy of Medical Sciences, Fuwai Hospital尚未招聘
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University尚未招聘绝经前乳腺癌 | 激素受体阳性乳腺癌 | 中高危乳腺癌患者 | 卵巢功能抑制联合芳香化酶抑制剂或他莫昔芬或托瑞美芬中国
-
Cancer Institute and Hospital, Chinese Academy...招聘中
-
Suzhou Connect Biopharmaceuticals, Ltd.完全的
-
Jiangsu HengRui Medicine Co., Ltd.主动,不招人根治性切除或消融后复发风险高的肝细胞癌 (HCC) 患者的辅助治疗中国
-
Peking Union Medical College Hospital完全的